Restricted heterochromatin formation links NFATc2 repressor activity with growth promotion in pancreatic cancer

Sandra Baumgart1, Elisabeth Glesel, Garima Singh

  • 1Signaling and Transcription Laboratory, Department of Gastroenterology, Philipps-University of Marburg, Marburg, Germany.

Gastroenterology
|November 15, 2011
PubMed
Abstract

Insights

Nuclear factor of activated T cells c2 (NFATc2) promotes pancreatic cancer by silencing the p15(INK4b) tumor suppressor. Inhibiting NFATc2 restores p15(INK4b) expression, halting tumor growth, suggesting a new therapeutic strategy.

Area of Science:

  • Molecular Oncology
  • Cancer Biology
  • Gene Regulation

Background:

  • Transcriptional silencing of the p15(INK4b) tumor suppressor pathway is crucial for overcoming cellular proliferation limits in cancer.
  • A novel pathway involving oncogenic nuclear factor of activated T cells c2 (NFATc2) targets the p15(INK4b) failsafe mechanism, promoting pancreatic cancer growth.

Purpose of the Study:

  • To elucidate the novel mechanism by which NFATc2 promotes pancreatic cancer.
  • To identify the functional link between NFATc2 repressor activity, p15(INK4b) silencing, and pancreatic cancer progression.
  • To evaluate the therapeutic potential of targeting NFATc2 in pancreatic cancer treatment.

Main Methods:

  • Utilized immunohistochemistry, real-time PCR, immunoblotting, and immunofluorescence microscopy for expression studies.
  • Assessed cancer growth in vitro using [(3)H]thymidine incorporation and colony formation assays, and in vivo using xenograft models.
  • Analyzed protein-protein interactions, promoter regulation, and histone modifications via immunoprecipitation, DNA pull-down, reporter assays, and chromatin immunoprecipitation.

Main Results:

  • NFATc2 was induced in late-stage pancreatic intraepithelial neoplasia and localized to tumor cell nuclei in advanced cancers.
  • NFATc2 targets the p15(INK4b) promoter, inducing heterochromatin formation and silencing via recruitment of Suv39H1 and HP1γ.
  • Inactivation of NFATc2 disrupted this repressor complex, restored p15(INK4b) expression, and inhibited pancreatic cancer growth both in vitro and in vivo.

Conclusions:

  • A novel mechanism of NFATc2-mediated gene regulation was described, linking its repressor activity to p15(INK4b) silencing in pancreatic cancer.
  • NFATc2 plays a critical role in regulating pancreatic cancer growth.
  • Inactivation of oncogenic NFATc2 represents a promising therapeutic strategy for pancreatic cancer treatment.

Related Concept Videos

Co-activators and Co-repressors02:04

Co-activators and Co-repressors

Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Canonical Wnt Signaling Pathway02:54

Canonical Wnt Signaling Pathway

The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which results in tumor...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...